Novartis Aktie
Kursziele der Novartis-Aktie in CHF
Diese Analysten bewerten die Novartis-Aktie
| Analyst | Kursziel | Abstand Kursziel | Datum | |
|---|---|---|---|---|
| RBC Capital Markets | 130,00 CHF | +0,60% | 08:01 Uhr | |
| Deutsche Bank AG | 120,00 CHF | -7,14% | 27.10.2026 | |
| Jefferies & Company Inc. | 110,00 CHF | -14,87% | 27.10.2026 | |
| Bernstein Research | 132,84 CHF | +2,80% | 27.10.2026 | |
| UBS AG | 116,00 CHF | -10,23% | 26.10.2026 | |
| Barclays Capital | 125,00 CHF | -3,27% | 26.10.2026 | |
| Goldman Sachs Group Inc. | 113,00 CHF | -12,55% | 01.10.2026 | |
| Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | 105,00 CHF | -18,74% | 11.09.2026 | |
| JP Morgan Chase & Co. | 135,00 CHF | +4,47% | 10.08.2026 | |
| DZ BANK | - | - | 22.07.2026 |
Kursziele im Branchenvergleich
| Aktie | Buy | Hold | Sell | Ø Kursziel | Abst. Kursziel |
|---|---|---|---|---|---|
| Abbott Laboratories | 0 | 0 | 0 | - | - |
| Alexion Pharmaceuticals Inc. | 0 | 0 | 0 | - | - |
| Allergan Inc. | 0 | 0 | 0 | - | - |
| APONTIS PHARMA | 0 | 0 | 0 | - | - |
| AstraZeneca PLC | 9 | 1 | 0 | 157,78 GBP | - |
| Bayer | 7 | 2 | 0 | 56,56 EUR | +21,37% |
| Celgene Corp. | 0 | 0 | 0 | - | - |
| EVOTEC SE | 1 | 2 | 0 | 5,70 EUR | +93,88% |
| Gilead Sciences Inc. | 0 | 0 | 0 | - | - |
| GSK PLC Registered Shs | 3 | 5 | 2 | 21,13 GBP | +15,37% |
| Johnson & Johnson | 0 | 0 | 0 | - | - |
| Merck Co. | 0 | 0 | 0 | - | - |
| Merck KGaA | 3 | 5 | 0 | 147,57 EUR | +1,32% |
| Mylan N.V. | 0 | 0 | 0 | - | - |
| Novartis AG | 1 | 8 | 1 | 119,65 CHF | -7,41% |
| Pfizer Inc. | 2 | 5 | 1 | 27,71 USD | -5,91% |
| Roche Holding AG (Inhaberaktie) | 0 | 0 | 0 | - | - |
| Roche Holding AG Inhaber-Partizipationsschein | 5 | 3 | 1 | 378,56 CHF | -5,08% |
| Sanofi S.A. | 5 | 5 | 0 | 90,13 EUR | +19,25% |
| STADA | 0 | 0 | 0 | - | - |
| Teva Pharmaceutical Industries Ltd. (spons. ADRs) | 0 | 0 | 0 | - | - |
| Vertex Pharmaceuticals Inc. | 0 | 0 | 0 | - | - |
| Warner Chilcott plc | 0 | 0 | 0 | - | - |